Dudediligence.

Cardiff Oncology, Inc

CRDFNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

68.5M

on 2026-06-30, from 44.7M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

20M40M60MMar2024JunSepDec$2.60Mar2025JunSepDecMar2026Jun

Newest

$400.0M

S-3 of 2025-02-27. 1 prospectus supplement filed under it since. S-3 ↗

$150.0M

Jefferies, agreement of 2021-03-12. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

432

Warrants of every class as tagged in the XBRL facts on 2026-06-30. 10-Q ↗

Cash

3.4 quarters

$34.5M on 2026-06-30 ÷ $10.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2026-07-14Public offering with warrants at $1.318,571,429$1.05$10.1M424B5 ↗
2024-12-10Public offering15,384,619$2.60$40.0M424B5 ↗